Christopher Bowden - Jun 9, 2025 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
Director
Signature
/s/ Lara Meisner, Attorney-in-Fact
Stock symbol
BCAX
Transactions as of
Jun 9, 2025
Transactions value $
$0
Form type
4
Date filed
6/10/2025, 04:26 PM
Previous filing
Sep 12, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bowden Christopher Director BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON /s/ Lara Meisner, Attorney-in-Fact 2025-06-10 0001608601

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCAX Stock Option (Right to Buy) Award $0 +23.7K $0.00 23.7K Jun 9, 2025 Common Stock 23.7K $11.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was awarded to the reporting person pursuant to the Issuer's 2024 Stock Option and Incentive Plan. The shares underlying this option shall vest upon the earlier of (i) June 9, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.